Biogen Quietly Resolves Whistleblower Case for $900M
Jul 21, 2022. Along with axing a Phase II schizophrenia program and touting the potential of lecanemab, its next shot at Alzheimer’s disease, Biogen announced Wednesday that it is forking over $900 million to resolve a lawsuit. The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors…
more “Biogen Quietly Resolves Whistleblower Case for $900M” »